Sunitinib 4/2
Checked 2026-09-09
Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET
One cycle
every 42 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Sunitinib Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT) | 50 mg once daily, 4 weeks on / 2 weeks off (37.5 mg continuous in NET) | Oral | D1-28 |
Cycles
until progression
42-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
CAPTEM
Advanced pancreatic neuroendocrine tumour
every 28 days
177Lu-DOTATATE (PRRT)
SSTR-positive gastroenteropancreatic NET after somatostatin analogue
every 56 days × 4
Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Nivolumab + ipilimumab (RCC)
Untreated advanced clear-cell RCC, IMDC intermediate or poor risk
every 21 days × 4
Pembrolizumab + axitinib
Untreated advanced clear-cell RCC, any IMDC risk
every 21 days
Imatinib
Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST
every 28 days